Pembrolizumab biosimilar is under clinical development by Sandoz Group and currently in Phase III for Melanoma. According to GlobalData, Phase III drugs for Melanoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pembrolizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pembrolizumab biosimilar overview
Pembrolizumab is under development for the treatment of stage II and III melanoma and metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC). The therapeutic candidate is a pembrolizumab biosimilar and administered through intravenous route as a solution for infusion. It acts by targeting programmed cell death protein (PD1).
Sandoz Group overview
Sandoz Group is a pharmaceutical company that develops and manufactures biosimilar products, generic medicines, and active pharmaceutical ingredients (API) for life-threatening diseases. The company’s biosimilar products comprise somatropin, epoetin alfa, rituximab, adalimumab, pegfilgrastim, natalizumab, and infliximab. Its product therapeutic areas include rheumatology, gastroenterology, dermatology, oncology, and neurology. Sandoz Group commercializes products under the brand names Erelzi, Hyrimoz, Zessly, Pyzchiva and Rixathon, Zarzio, Zarxio, Binocrit?, Ziextenzo and Cimerli. The company operates through its subsidiaries in the Netherlands, France, Australia, India, Poland, Germany, Japan, the UK, Belgium and Denmark, among others. Sandoz Group is headquartered in Rotkreuz, Zug, Switzerland.
For a complete picture of Pembrolizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
